Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-05
2011-11-08
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08053461
ABSTRACT:
A compound or a pharmaceutically acceptable salt thereof of the present invention is represented by the following general formula (I):[wherein, R1to R8may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9(wherein R9represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents a sulfur atom, an oxygen atom or NR10(wherein R10represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group or a C1-C6 alkoxy group)].
REFERENCES:
patent: 2003/0219380 (2003-11-01), Fong et al.
patent: 2003-523340 (2003-08-01), None
patent: WO 01/60814 (2001-08-01), None
patent: WO 02/081466 (2002-10-01), None
patent: WO 2005/058309 (2005-06-01), None
Janne et al ‘Factors underlying sensitivity of cancers to small-molecule kinase inhibitors’ Nature Reviews: Drug Discovery, vol. 8, p. 709-723, 2009.
Suggitt et al ‘50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches’ Clinical Cancer Research, vol. 11, p. 971-981, 2005.
Cuypers, H. Theo, et al. Murine Leukemia Virus-Induced T-Cell Lymphomagenesis: Integration of Proviruses in a Distinct Chromosomal Region; Cell, May 1984, pp. 141-150, vol. 37.
Selten, Gerard, et al. “Proviral Activation of the Putative Oncogene Pim-1 in MuLV induced T-cell lymphomas.” The EMBO Journal , 1985 pp. 1793-1798, vol. 4 No. 7.
Bachmann, Malte, et al. “The Serine/threonine Kinase Pim-1.” The International Journal of Biochemistry & Cell Biology, 2005, pp. 726-730, vol. 37.
Chifumi Fujii, et al. “Aberrant Expression of Serine/Threonine Kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.” International J. Cancer, 2005, pp. 209-218, vol. 114.
Li, Ying-Yi, et al. “Pim-3, a Proto-Oncogene with Serine/Threonine Kinase Activity, Is Aberrantly Expressed in Human Pancreatic Cancer and Phosphorylates Bad to Block Bad-Mediated Apoptosis in Human Pancreatic Cancer Cell Lines.” Cancer Research. Jul. 1, 2006, pp. 6741-6747, vol. 66(13).
Mologni, Luca et al. Inhibition of RET Tyrosine Kinase by SU5416, Journal of Molecular Endocrinolgy, 2006, pp. 199-212, vol. 37, No. 2.
Accession No. (AN): 203127644 Chemcasts Catalog Name (CO): Aurora Screening Library Publication Date (PD): Jan. 1, 2007 Order Number (ON): kmy-026850 Chemical Name (CN): 1H-Isoindole-1, 3 (2H)-dione, 1-[[5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2-furanyl]methyl]- CAS Registry No. (RN): 697741-84-7, Supplemetary Term (ST) Chemical Library.
Kobayashi Masataka
Mori Takao
Shao Jun
Shinobu Noriaki
Arent & Fox LLP
Fetterolf Brandon
Stone Christopher R
Theravalues Corporation
LandOfFree
Oxindole derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxindole derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxindole derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304875